Quality Control for Mesenchymal Stromal Cells (MSCs)

The implementation of quality control (QC) measures in mesenchymal stromal cells (MSCs) is essential to ensure their safety, efficacy, and compliance with international regulatory standards. The quality of MSCs directly impacts the effectiveness of cell therapies, making it imperative to conduct a thorough evaluation at each stage of production and clinical application. These assessments follow the guidelines established by the International Society for Cellular Therapy (ISCT) and additionally include evaluations of viability, purity, differentiation potential, genetic stability, and absence of contamination to ensure their safe use in cell-based therapies.

Phenotypic Characterization

The proper identification of MSCs is critical to ensuring their therapeutic functionality. Specific surface markers are assessed using flow cytometry, which helps exclude unwanted cell populations, such as hematopoietic or immune cells, that could compromise treatment safety and cause adverse effects in patients.

Positive markers: CD73, CD90, CD105.

• CD105: Regulates cell proliferation, migration, and differentiation.
• CD73: Plays a role in modulating immune responses and inflammatory processes.
• CD90: Regulates cell adhesion, proliferation, and differentiation.

Negative markers: CD34, CD45, CD14, CD19, HLA-DR. The absence of these markers confirms that MSCs are not contaminated with hematopoietic or immune cells, which is crucial to prevent adverse reactions in recipients.

• CD45: A hematopoietic cell marker (white blood cells); its absence confirms that the cell population is not of hematopoietic origin.
• CD34: Found in hematopoietic and endothelial progenitor cells; its absence differentiates MSCs from hematopoietic progenitors.
• CD14/CD11b: Monocyte and macrophage markers; their absence indicates the population is not of myeloid lineage.
• CD79α/CD19: Specific markers for B cells; their absence confirms that the cell population is not lymphocytic.
• HLA-DR: A major histocompatibility complex class II (MHC-II) molecule; its absence under baseline conditions indicates that MSCs do not immediately trigger an immune response.

Differentiation Potential

The versatility of MSCs lies in their ability to differentiate into mesodermal cell lineages, a fundamental criterion for their use in regenerative therapies. Differentiation assays and specific staining techniques are used to demonstrate this capability:

• Osteogenesis: Alizarin Red staining indicates calcium deposition in the bone matrix.
• Chondrogenesis: Alcian Blue staining highlights proteoglycan production in cartilage.
• Adipogenesis: Oil Red O staining marks lipid accumulation in adipocytes.

Additionally, MSCs must maintain their proliferative capacity during cell passages without losing their differentiation potential, ensuring their long-term stability and therapeutic efficacy.

Cell Viability

Cell viability is a critical parameter for assessing the quality of MSCs before administration. It is determined using trypan blue exclusion assays or fluorescent dyes such as propidium iodide (PI) and carboxyfluorescein succinimidyl ester (CFSE). A viability level above 80% is considered optimal to ensure an adequate therapeutic response.

Donor Serology and Safety

Serological testing is essential to minimize the risk of disease transmission to recipients. Serum, plasma, saliva, or urine samples are analyzed to detect potentially harmful pathogens. Some of the tests include:

• Anti-HIV 1-2 antibodies.
• Hepatitis B surface antigen (HBsAg).
• Anti-hepatitis C antibodies.
• Antibodies against Treponema pallidum (syphilis).
• Anti-Trypanosoma cruzi antibodies.
• Anti-cytomegalovirus antibodies.
• Anti-Toxoplasma gondii antibodies.
• Anti-Herpes simplex virus type I and II antibodies.
• Anti-hepatitis A antibodies.
• Anti-Chlamydia trachomatis antibodies.

In addition to these tests, a comprehensive medical history of the donor is essential to rule out infectious, immune, or genetic conditions that may affect cell quality.

Microbiological Analysis

Microbiological testing ensures that MSCs are free from contaminants that could compromise their safety. The following tests are performed:

• Microbiological cultures: Detect bacteria, fungi, and mycoplasmas that could cause infections in the patient.
• PCR tests: Identify the presence of viruses such as CMV, Epstein-Barr, and parvovirus B19 to ensure that cells are safe for clinical use.
• Bacterial endotoxin detection: The Limulus Amebocyte Lysate (LAL) assay is used to detect endotoxins, as their presence can trigger dangerous inflammatory responses in patients.

Genetic Evaluation

Genetic analysis of MSCs is crucial to rule out chromosomal abnormalities or mutations that could compromise their safety and efficacy. The following aspects are assessed:

Conventional karyotyping: Detects chromosomal aberrations that may arise during prolonged culture.

Oncogene and genetic stability analysis: Key genes such as P53, C-MYB, C-MYC, and K-RAS are examined, as they regulate cell cycle progression and proliferation. Alterations in these genes may increase the risk of malignant transformation.

• P53: Regulates the cell cycle and apoptosis in response to DNA damage, preventing mutation accumulation and cancer development.
• C-MYB: Controls proliferation, differentiation, and apoptosis in hematopoietic cells; its overexpression is associated with leukemia and other hematological cancers.
• C-MYC: Promotes cell proliferation by driving cell cycle progression; its overexpression is linked to various cancers, including Burkitt’s lymphoma and colorectal cancer.
• K-RAS: Part of the RAS protein family, involved in cellular signaling for growth, differentiation, and survival. Mutations in K-RAS are associated with lung, pancreatic, and colorectal cancers.

Genomic instability assays: Identify structural DNA changes that could impact cellular functionality and clinical safety.

Preclinical Functional Testing in Animal Models

Before clinical application, MSCs must demonstrate their efficacy in animal models. These tests assess their ability to regenerate tissues, modulate inflammation, and stimulate cellular repair. Some of the preclinical evaluations include:

• Bone injury models: Assess osteogenic potential.
• Arthritis models: Determine immunomodulatory properties.
• Ischemia models: Evaluate angiogenic and neuroprotective capacities.

Preclinical studies provide key insights into MSC safety and functionality, helping design more effective therapeutic strategies.

Conclusions

Quality control is essential to ensure the safety and efficacy of MSCs in clinical applications. Implementing rigorous, standardized protocols enables the production of high-quality cell products, minimizing risks and optimizing therapeutic benefits in regenerative medicine.

Adhering to these strategies not only meets international regulatory guidelines but also enhances the reproducibility and effectiveness of MSC-based therapies.

At Baja Regenerative, we are committed to applying the highest standards in the development and quality control of our cell therapies. If you want to learn more about how our cells can benefit your patients, contact us, and let’s work together to offer cutting-edge treatments with maximum safety and efficacy.

References

• Dominici, M., et al. (2006). “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.” Cytotherapy, 8(4), 315-317. [DOI: 10.1080/14653240600855905].
• Pittenger, M. F., et al. (1999). “Multilineage potential of adult human mesenchymal stem cells.” Science, 284(5411), 143-147. [DOI: 10.1126/science.284.5411.143].
• Reyes Martínez, V., et al. “Células estromales mesenquimales representan una opción terapéutica en la esclerosis sistémica cutánea.” Revista Colombiana de Reumatología, 27(3), 145-158. Retrieved from https://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-celulas-estromales-mesenquimales-representan-una-S0121812320301481.
• Cases-Perera, O., et al. (2022). “Efecto del uso de secretoma de células madre mesenquimales sobre la viabilidad y proliferación de fibroblastos en modelos in vitro.” Revista Española de Cirugía Plástica, 56(4), 123-134. Retrieved from https://scielo.isciii.es/scielo.php?pid=S0376-78922022000400003&script=sci_arttext&utm.
• García-Bermejo, I., & de Ory, F. (2017). “Diagnóstico rápido en serología.” Enfermedades Infecciosas y Microbiología Clínica, 35(2), 123-130. Retrieved from https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-diagnostico-rapido-serologia-S0213005X17300095.
• Domínguez, L. M., et al. (2020). “Células madre/estromales mesenquimales: su potencial terapéutico en medicina regenerativa.” Medicina (Buenos Aires, Argentina), 80(9), 696-710. Retrieved from https://www.scielo.org.ar/scielo.php?pid=S0025-76802020000900696&script=sci_arttext.
• Ospina Pérez, M., & Muñetón Peña, C. M. (2011). “Alteraciones del gen c-Myc en la oncogénesis.” Iatreia, 24(4), 389-401. Universidad de Antioquia.

 

Author: Biol. Carlos David Reyes Padilla